Sodium phosphate enema warning may be reconsidered by FDA after feedback meeting.
This article was originally published in The Tan Sheet
Executive Summary
SODIUM PHOSPHATE ENEMA FINAL RULE WARNING RECONSIDERATION by FDA may be possible, the agency indicated at a July 15 "feedback" meeting on the agency's final rule that covers warnings and directions for OTC sodium phosphate laxative products. The meeting was held in response to comments submitted by C.B. Fleet and the private label firm Nutramax that the wording of the warning in the May 21 final rule differs materially from the proposed rule and was changed without allowing public comment ("The Tan Sheet" July 6, p. 6). C.B. Fleet and Nutramax attended the meeting, as did representatives of the Nonprescription Drug Manufacturers Association. Lynchburg, Va.-based C.B. Fleet manufactures Fleet Phospho-Soda Oral Saline Laxative, Fleet Ready-to-Use Enema and Fleet Enema for Children.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning